(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






Health Care Sector

CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial

April 20th, 2017

Bedminster, NJ / CRWE PRESS RELEASE / April 20, 2017 - CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,. Read more

Diplomat Will Dispense ZEJULA(TM) to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

April 19th, 2017

The nation’s largest independent specialty pharmacy has been selected to the specialty pharmacy panel to dispense ZEJULA™ (niraparib). FLINT, Mich. / CRWE PRESS RELEASE / April 19, 2017 – Diplomat Pharmacy, Inc. (NYSE: DPLO), ha. Read more

Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine

April 18th, 2017

- Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology - - Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development - - Existing Investors OrbiMed Advisors. Read more

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

April 17th, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 17, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has scheduled the New Drug Application (NDA) for n. Read more

CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer

April 16th, 2017

ROCKVILLE, Md. / CRWE PRESS RELEASE / April 14, 2017 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, reported today that along with the inv. Read more

Abbott and Alere Amend Terms of Merger Agreement

April 16th, 2017

ABBOTT PARK, Ill. and WALTHAM, Mass. / CRWE PRESS RELEASE / April 14, 2017 - Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today that the companies have agreed to amend the existing terms of their agreement for Abbott's acquisition of A. Read more

AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues

April 13th, 2017

CAMBRIDGE, Mass. / CRWE PRESS RELEASE / April 13, 2017 - AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Is. Read more

Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities

April 12th, 2017

Los Angeles, California / CRWE PRESS RELEASE / April 12, 2017 - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”) today, April 12, 2017, announced that the U.S. Food and Drug Administration (FDA) has agreed to schedule an end of. Read more

Alere Achieves FDA Clearance for Alere(TM) Reader Platform and Alere BinaxNOW(R) Influenza A & B Card 2

April 11th, 2017

WALTHAM, Mass. / CRWE PRESS RELEASE / April 11, 2017 - Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that its Alere™ Reader, a diagnostic analyzer that can be used in both point-of-care and laboratory settings, h. Read more

Takeda Enters into Strategic Collaboration with NuBiyota for Microbiome Therapeutics

April 11th, 2017

Osaka, Japan / CRWE PRESS RELEASE / April 11, 2017 - Takeda Pharmaceutical Company Limited (TSE:4502) today announced a strategic collaboration with NuBiyota LLC for the development of Microbial Ecosystem Therapeutic products for gastroenterolog. Read more

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting

April 02nd, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 (nera. Read more

Load More Content